All In MedTech

FDA Clearance Tracker · K241724

Cytal® Wound Matrix; Cytal® Burn Matrix

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 20, 2026Latest source record: Jul 11, 2024 (this decision)Source: openFDAMethods & limitations

510(k)

Decided

Jul 11, 2024

Substantially Equivalent

Time to decision

27 days

Received Jun 14, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Special

Device class

Unclassified

The decision

FDA number
K241724
Device name
Cytal® Wound Matrix; Cytal® Burn Matrix
Applicant
Acell, Inc.
Applicant location
Columbia, MD
Received
Jun 14, 2024
Decided
Jul 11, 2024
Decision
Substantially Equivalent
Submission type
Special

Device type

Device class
Unclassified

Every decision under product code KGN

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code KGN. The earliest in FDA's data is K790496, decided May 3, 1979.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Acell, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.